Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Лимфома из клеток мантийной зоны: клинические особенности и возможности терапии
Лимфома из клеток мантийной зоны: клинические особенности и возможности терапии
Ю.Ю. Лорие. Лимфома из клеток мантийной зоны: клинические особенности и возможности терапии. Онкология. 2006; 1: 13-17.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Lennert K, Stein H, Kaiserling E. Cytological and functional criteria for the classification of malignant lymphoma. Br J Cancer 1975; 31: 29–43.
2. Berard CW, Dorfman RF. Histopathology of malignant lymphomas. Clin Hematol 1974; 3: 39.
3. Сornes JS. Multiple lymphomatous polyposis of the gastrointestinal tract. Cancer 1961; 14: 249–57.
4. Williams ME, Densmore JJ. Biology and therapy of mantle cell lymphoma Curr Opin Oncol 2005; 17: 425–31.
5. Лорие Ю.Ю. Лимфома из клеток мантийной зоны: клинические формы, морфологические варианты, диагностика и лечение. Автореф. дис. … канд. мед. наук. М., 2005.
6. Kienle D, Krober A, Katzenberger T et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: corellation with genomic aberrations, clinical characteristics and outcome. Blood First edition paper, prepublished online July 3, 2004.
7. Tort F, Camacho E, Bosch F et al. Familial lymphoid neoplasms in patients with mantle cell lymphoma. Haematologica 2004; 89: 314–9.
8. Обухова Т.Н., Лорие Ю.Ю., Водинская Л.А. и др. Цитогенетика лимфомы из клеток мантийной зоны. Тер. архив. 2004; 7: 70–7.
9. Romaguera JE, Fayad L, Rodriguez MA et al. High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. Published Ahead of Print on September 6, 2005 as 10.1200/JCO.2005.01.1825.
10. Vandenberghe E, Ruiz de Elvira C, Loberiza FR et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800.
11. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival. J Clin Oncol 2002; 20: 1288–94.
12. Kaufmann H, Raderer M, Wohrer S et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2269–71.
13. Unterhalt M, Hermann R, Koch P. Long-term Interferon-a maintenence prolongs remission duration in advanced low-grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. ASH 1996, WB Saunders, Orlando, FL, Abstr#2683.
14. Ghielmini M, Shmitz S-FH, Cogliatti S et al. Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK) J Clin Oncol 2005; 23: 705–11.
15. O’Connor OA, Wright J, Moskowitz C et al. Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma. J Clin Oncol 2005; 23: 676–84.
16. Kaufmann H, Raderer M, Wohrer S et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Blood 2004; 104: 2269–71.
2. Berard CW, Dorfman RF. Histopathology of malignant lymphomas. Clin Hematol 1974; 3: 39.
3. Сornes JS. Multiple lymphomatous polyposis of the gastrointestinal tract. Cancer 1961; 14: 249–57.
4. Williams ME, Densmore JJ. Biology and therapy of mantle cell lymphoma Curr Opin Oncol 2005; 17: 425–31.
5. Лорие Ю.Ю. Лимфома из клеток мантийной зоны: клинические формы, морфологические варианты, диагностика и лечение. Автореф. дис. … канд. мед. наук. М., 2005.
6. Kienle D, Krober A, Katzenberger T et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: corellation with genomic aberrations, clinical characteristics and outcome. Blood First edition paper, prepublished online July 3, 2004.
7. Tort F, Camacho E, Bosch F et al. Familial lymphoid neoplasms in patients with mantle cell lymphoma. Haematologica 2004; 89: 314–9.
8. Обухова Т.Н., Лорие Ю.Ю., Водинская Л.А. и др. Цитогенетика лимфомы из клеток мантийной зоны. Тер. архив. 2004; 7: 70–7.
9. Romaguera JE, Fayad L, Rodriguez MA et al. High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. Published Ahead of Print on September 6, 2005 as 10.1200/JCO.2005.01.1825.
10. Vandenberghe E, Ruiz de Elvira C, Loberiza FR et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800.
11. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival. J Clin Oncol 2002; 20: 1288–94.
12. Kaufmann H, Raderer M, Wohrer S et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2269–71.
13. Unterhalt M, Hermann R, Koch P. Long-term Interferon-a maintenence prolongs remission duration in advanced low-grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. ASH 1996, WB Saunders, Orlando, FL, Abstr#2683.
14. Ghielmini M, Shmitz S-FH, Cogliatti S et al. Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK) J Clin Oncol 2005; 23: 705–11.
15. O’Connor OA, Wright J, Moskowitz C et al. Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma. J Clin Oncol 2005; 23: 676–84.
16. Kaufmann H, Raderer M, Wohrer S et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Blood 2004; 104: 2269–71.
Авторы
Ю.Ю. Лорие
ГНЦ РАМН, Москва
ГНЦ РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.